LAUNCH DIAGNOSTICS LIMITED

Risk Rating: MEDIUM

Justification: The company exhibits strong solvency and consistent profitability, supported by a solid asset base and a long operational history. However, recent changes in ownership, significant director turnover, and the transfer of cash reserves to the parent group introduce moderate operational and liquidity monitoring requirements that prevent a lower risk rating.

Key Concerns

1. Cash Transfer to Parent Group: Cash balances decreased significantly from £2,871,107 to £1,264,768 year-on-year. The strategic report notes this reflects a transfer of surplus funds into a Group cash pool to support wider Group expansion plans. This reduces the subsidiary's independent liquidity and ties its financial flexibility to the parent company's strategic decisions.
2. Governance and Ownership Transition: The company experienced considerable board turnover in 2025, with multiple director appointments and resignations (including the departure of Xxxxxx Xxxxxxxxname shown to subscribers and Xxxxxx Xxxxxxxxname shown to subscribers in November 2025). The strategic report explicitly identifies a "recent change of ownership" as a principal risk, which may create operational uncertainty as the business adjusts to new structures.
3. Customer Concentration: A large portion of the company's revenue is derived from the National Health Service (NHS). While management notes there is no forecast reduction in trade, this reliance exposes the company to public sector budget constraints and macroeconomic pressures on healthcare spending.

Positive Indicators

1. Robust Financial Position: The company maintains a healthy balance sheet with net assets of £8,012,766 against total liabilities of £2,023,072. Profit after tax increased from £708,878 to £860,813, and turnover remained stable at approximately £14.46 million.
2. Strong Regulatory Compliance: The company files full, audited accounts (audited by Saffery LLP) and has no overdue filings for either accounts or confirmation statements. The auditor's report indicates no material uncertainties regarding the going concern basis for at least 12 months from the approval date.
3. Long Operational History: Incorporated in 1989, the company has a long-standing presence in the diagnostic reagent and hospital laboratory instrumentation market, indicating established operational stability and resilience in a rapidly evolving scientific sector.

Due Diligence Notes

1. Parent Company Financials: Investigate the financial stability, debt structure, and expansion plans of Launch Diagnostics (Holdings) Limited, given that the subsidiary's cash is being utilized for group-level initiatives.
2. Ownership Change Context: Examine the details surrounding the recent change of ownership and the rationale behind the rapid turnover of directors in 2025 to ensure there are no underlying governance disputes or strategic misalignments.
3. Margin Pressure: Monitor the slight decrease in gross margin (from 47.9% to 46.7%) and assess how sales mix changes, foreign currency exposures (post-Brexit), and inflationary pressures may impact future profitability.

Names of the people mentioned are shown to subscribers. See subscription